Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282004 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT05282004 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) that has completed, run by Sandoz. The registered enrollment target is 36 participants, below the 204-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (82% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05282004, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
Conditions Studied
Interventions
- DRUG SOK583A1
Study Locations (5)
California
- Sandoz Investigational Site - Poway
Georgia
- Sandoz Investigational Site - Marietta
Illinois
- Sandoz Investigational Site - Oak Forest
New York
- Sandoz Investigational Site - Liverpool
Virginia
- Sandoz Investigational Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05282004
The ClinicalTrials.gov registry entry for NCT05282004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (82% lower). The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which SOK583A1 is the first listed.
NCT05282004 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05282004 about?
NCT05282004 is a clinical study titled "Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit". This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
What is the current status of trial NCT05282004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2022-05-16. Estimated completion is 2022-09-07.
What conditions does trial NCT05282004 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT05282004?
The interventions under investigation include: SOK583A1 (DRUG).
Who is sponsoring clinical trial NCT05282004?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282004 being conducted?
This trial has 5 study locations across California, Georgia, Illinois, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
COMPLETED · Phase 3
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.